相关实验视频

Updated: Jun 22, 2025

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

西维莱沙特通过抑制PI3K/AKT/mTOR信号通路来改善急性肺损伤

Yaqing Zhou¹, Haiyan Wang², Aiming Liu¹

¹Department of Critical Care Medicine, Hai'an People's Hospital, Hai'an County, Nantong City, Jiangsu Province, China.

|June 27, 2024

概括

西维莱沙特通过减少炎症和改善肺功能,有效地治疗败血症中的急性肺损伤 (ALI). 它通过抑制PI3K/AKT/mTOR信号通路而起作用,为ALI提供了潜在的治疗干预.

科学领域:

肺部医学肺部医学
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

急性肺损伤 (ALI) 和急性呼吸困难综合征 (ALI/ARDS) 是具有显著发病率和死亡率的危急疾病.
目前对ALI/ARDS的治疗方法有限,需要探索新型治疗剂.

研究的目的:

在ALI/ARDS的小鼠模型中研究sivelestat的治疗疗效.
阐明西维莱斯塔特作用的潜在分子机制,重点关注PI3K/AKT/mTOR通路.

主要方法:

通过注射脂聚糖胺 (LPS) 来建立ALI/ARDS的体内大鼠模型.
通过病理检查,动脉血液气体分析 (PaO2,PaO2/FiO2) 和肺湿/干重量比来评估肺损伤.
使用ELISA量化了炎症和细胞粘附标记 (NE,VCAM-1,IL-8,TNF-α) 的数量.
PI3K/AKT/mTOR通路的激活通过实时RT-PCR和Western blotting来确定.

主要成果:

西维莱斯塔治疗显著改善了肺功能,由增加的PaO2和PaO2/FiO2证明,并降低了肺湿/干比和损伤得分.
在施用sivelestat后,观察到炎症标志物 (NE,VCAM-1,IL-8,TNF-α) 的剂量依赖性降低.
西维莱沙特显著降低了Bax,PI3K,Akt和mTOR的表达,同时提高了Bcl-2的表达,表明PI3K/AKT/mTOR通路的调节.

结论:

西维莱斯塔特在败血症中对ALI表现出显著的治疗效果.
该机制涉及PI3K/AKT/mTOR信号通路的抑制.
西维莱斯塔特是一种有前途的治疗候选物来治疗ALI/ARDS.

更多相关视频

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins

Published on: May 24, 2024

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury

Published on: May 21, 2018

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...